Literature DB >> 9821156

Influence of repeated levodopa administration on rabbit striatal serotonin metabolism, and comparison between striatal and CSF alterations.

D A Loeffler1, P A LeWitt, P L Juneau, D M Camp, A J DeMaggio, M K Havaich, P E Milbury, W R Matson.   

Abstract

Parkinson's disease (PD) is characterized by decreased striatal dopamine, but serotonin (5-HT) is also reduced. Because 5-HT decreases following a single levodopa injection, levodopa has been suggested to contribute to PD's serotonergic deficits. However, in a recent study, rat striatal serotonin levels were reported to increase following 15-day levodopa administration. To address this issue, we administered levodopa (50 mg/kg) to rabbits for 5 days, then measured serotonin, its precursors tryptophan and 5-hydroxytryptophan (5-HTP), and its major metabolite 5-hydroxyindole-acetic acid (5-HIAA) in striatum and CSF. Striatal serotonin and tryptophan were unchanged, while 5-HTP and 5-HIAA increased 4- and 7-fold, respectively. CSF 5-HTP and 5-HIAA were also significantly increased. In levodopa-treated animals, 5-HTP concentrations were moderately correlated (r = 0.679) between striatum and CSF, while weak correlations were present between striatal and CSF concentrations of both serotonin and 5-HIAA. These results suggest that repeated levodopa treatment increases striatal serotonin turnover without changing serotonin content. However, levodopa-induced alterations in striatal serotonin metabolism may not be accurately reflected by measurement of serotonin and 5-HIAA in CSF.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9821156     DOI: 10.1023/a:1020923919560

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  43 in total

1.  Depression and Parkinson's disease.

Authors:  R Mayeux; Y Stern; J B Williams; M Sano; L Cote
Journal:  Adv Neurol       Date:  1987

2.  The influence of microelectrophoretically applied biogenic amines, cholinomimetics and procaine on synaptic excitation in the corpus striatum.

Authors:  A Herz; W Zieglgänsberger
Journal:  Int J Neuropharmacol       Date:  1968-05

Review 3.  Monoamine oxidase activity and localisation in the brain and the activity in relation to psychiatric disorders.

Authors:  L Oreland; Y Arai; A Stenström; C J Fowler
Journal:  Mod Probl Pharmacopsychiatry       Date:  1983

4.  Chronic L-dopa administration decreases striatal accumulation of dopamine from exogenous L-dopa in rats with intact nigrostriatal projections.

Authors:  E Melamed; M Globus; E Friedlender; J Rosenthal
Journal:  Neurology       Date:  1983-07       Impact factor: 9.910

5.  Excitation of caudate-putamen neurons following stimulation of the dorsal raphe nucleus in the rat.

Authors:  C P Vandermaelen; A C Bonduki; S T Kitai
Journal:  Brain Res       Date:  1979-10-19       Impact factor: 3.252

6.  Central serotonin metabolism and frequency of depression.

Authors:  H M van Praag; S de Haan
Journal:  Psychiatry Res       Date:  1979-12       Impact factor: 3.222

7.  Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease.

Authors:  G M Halliday; P C Blumbergs; R G Cotton; W W Blessing; L B Geffen
Journal:  Brain Res       Date:  1990-02-26       Impact factor: 3.252

8.  Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain.

Authors:  F C Zhou; S Bledsoe; J Murphy
Journal:  Brain Res       Date:  1991-08-09       Impact factor: 3.252

9.  [L-5-hydroxytryptophan(L-5-HTP) therapy of Parkinson's disease. 2].

Authors:  I Sano; K Taniguchi
Journal:  Munch Med Wochenschr       Date:  1972-10-06

10.  Unilateral destruction of dopamine pathways increases ipsilateral striatal serotonin turnover in rats.

Authors:  P J Karstaedt; H Kerasidis; J H Pincus; R Meloni; J Graham; K Gale
Journal:  Exp Neurol       Date:  1994-03       Impact factor: 5.330

View more
  4 in total

1.  Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease.

Authors:  S Engelborghs; B Marescau; P P De Deyn
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

2.  Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease.

Authors:  Thomas Müller; Siegfried Muhlack
Journal:  J Neural Transm (Vienna)       Date:  2008-03-12       Impact factor: 3.575

3.  Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept.

Authors:  R Kaddurah-Daouk; S H Boyle; W Matson; S Sharma; S Matson; H Zhu; M B Bogdanov; E Churchill; R R Krishnan; A J Rush; E Pickering; M Delnomdedieu
Journal:  Transl Psychiatry       Date:  2011       Impact factor: 6.222

Review 4.  Many Faces of Parkinson's Disease: Non-Motor Symptoms of Parkinson's Disease.

Authors:  Hye Mi Lee; Seong-Beom Koh
Journal:  J Mov Disord       Date:  2015-05-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.